VEGF/Angiogenesis Signaling: VEGFR Kinase Activation, HIF-1α Regulation, and Vascular Research Tools

# VEGF/Angiogenesis Signaling: VEGFR Kinase Activation, HIF-1α Regulation, and Vascular Research Tools

For Research Use Only (RUO). Not intended for diagnostic, therapeutic, or clinical applications.

---

Introduction: The Angiogenic Switch and VEGF Biology

Angiogenesis — the sprouting of new blood vessels from existing vasculature — is a tightly regulated process governed by a dynamic balance between pro- and anti-angiogenic signals. Physiologically essential for wound healing, embryonic development, and the female reproductive cycle, angiogenesis becomes pathologically activated in solid tumors, diabetic retinopathy, and chronic inflammatory diseases. The vascular endothelial growth factor (VEGF) family, acting through receptor tyrosine kinases (VEGFRs), constitutes the master regulator of this process.

The VEGF/VEGFR axis was first characterized in the early 1990s following the identification of vascular permeability factor (VPF) by Dvorak and colleagues, and its subsequent cloning as VEGF-A by Ferrara and Henzel (1989). Over three decades of research have established VEGF-A as the dominant driver of pathological angiogenesis, culminating in FDA approval of bevacizumab (anti-VEGF-A monoclonal antibody) in 2004 — a landmark demonstration that anti-angiogenic therapy could improve cancer outcomes.

This article provides a mechanistic analysis of VEGF ligand biology, receptor kinase activation, downstream signal transduction through PI3K/AKT/eNOS and MAPK/ERK pathways, DLL4-Notch-mediated tip/stalk cell specification, and HIF-1α transcriptional regulation of VEGF expression — with emphasis on validated research tools and experimental approaches for studying these pathways.

---

VEGF Ligand Family: Isoforms, Receptors, and Binding Specificity

The VEGF family comprises five mammalian members (VEGF-A, -B, -C, -D, and placental growth factor/PlGF) plus the viral homolog VEGF-E. Each ligand displays distinct receptor binding profiles:

VEGF-A itself exists as multiple splice isoforms generated by alternative exon inclusion: VEGF-A121, VEGF-A145, VEGF-A148, VEGF-A165, VEGF-A189, and VEGF-A206 (human numbering). The most abundant and biologically critical isoform, VEGF-A165, is a homodimeric glycoprotein (~45 kDa) with heparin-binding capacity that allows tethering to extracellular matrix. VEGF-A121 lacks heparin-binding exons 6-7 and is freely diffusible; VEGF-A189 is almost entirely matrix-bound. Plasmin-mediated cleavage of matrix-bound isoforms generates bioactive fragments with distinct receptor signaling properties.

Neuropilins (NRP1/2) function as co-receptors that enhance VEGFR2 signaling by stabilizing VEGF-A165/VEGFR2 complexes and recruiting intracellular adaptor proteins including synectin (GIPC1). NRP1 associates with VEGF-A165 through its b1b2 domains binding the C-terminal DKPRR sequence encoded by exon 8b; NRP2 shows preferential binding to VEGF-A145 and VEGF-C.

---

VEGF Receptor Architecture and Kinase Activation Mechanism

The three VEGF receptor tyrosine kinases (VEGFR1/FLT1, VEGFR2/KDR/FLK-1, VEGFR3/FLT4) share a common structural topology: seven extracellular immunoglobulin-like (Ig) domains, a single transmembrane helix, a juxtamembrane domain, a split kinase domain interrupted by a kinase insert domain (KID), and a C-terminal tail.

VEGFR2: The Primary Angiogenic Signal Transducer

VEGFR2 (KDR in humans, Flk-1 in mice) is the dominant signaling receptor for angiogenesis. Ligand binding induces receptor dimerization and transphosphorylation at multiple tyrosine residues:

Key VEGFR2 phosphorylation sites:

• •Y1054/Y1059 (activation loop): Essential for full kinase activation; analogous to the activation loop Tyr in other RTKs
• •Y1175 (C-terminal tail): Major docking site for PLCγ1 and SHB adaptor; required for ERK and eNOS activation
• •Y1214 (C-terminal tail): Docking site for NCK and FYN; regulates actin cytoskeleton remodeling
• •Y951 (KID): Docking site for VRAP/TSAd adaptor, recruits SRC for PI3K activation
• •Y801 (juxtamembrane): Binds SRC SH2 domain; modulates receptor trafficking

The unphosphorylated VEGFR2 kinase domain adopts an autoinhibited conformation with the activation loop (DFG-Asp to APE-Glu) blocking the substrate binding cleft. Ligand-driven dimerization brings the two kinase domains into proximity, enabling trans-autophosphorylation of Y1054/Y1059, which rotates the activation loop out of the substrate cleft and increases catalytic activity ~100-fold.

VEGFR1: Decoy Receptor and Signal Modulator

VEGFR1 (FLT1) binds VEGF-A with ~10-fold higher affinity than VEGFR2 (Kd ~10 pM vs. ~100 pM) but has ~10-fold lower intrinsic kinase activity due to a suppressive sequence in the juxtamembrane domain. Consequently, VEGFR1 functions primarily as a decoy receptor that sequesters VEGF-A away from VEGFR2 — a critical negative-feedback mechanism limiting angiogenic signaling. A soluble isoform (sFLT1) generated by alternative splicing lacks transmembrane and intracellular domains; it circulates as a potent VEGF-A trap and is deficient in preeclampsia.

VEGFR1 does transduce productive signals in monocytes/macrophages (PI3K/AKT pathway), in PlGF-driven pathological angiogenesis, and in tumor-associated macrophage recruitment.

VEGFR3: Lymphangiogenic Signaling

VEGFR3 (FLT4) is the primary receptor for VEGF-C and VEGF-D, expressed predominantly on lymphatic endothelial cells in adults (though expressed broadly during embryogenesis). VEGFR3 can form homodimers (VEGF-C/D) or heterodimers with VEGFR2. Its proteolytic processing into a disulfide-linked two-chain form in the fifth Ig domain is required for efficient cell surface expression. VEGFR3 mutations cause Milroy disease (hereditary lymphedema).

---

PI3K/AKT/eNOS Signaling: Vascular Permeability and Endothelial Survival

The PI3K/AKT pathway downstream of VEGFR2 coordinates endothelial cell survival, migration, proliferation, and nitric oxide (NO) production.

Receptor-PI3K Coupling

Activated VEGFR2 recruits the regulatory subunit p85α of class IA PI3K through pY951 (via VRAP/TSAd adaptor and SRC) and through direct SH2 domain interactions. PI3K phosphorylates PtdIns(4,5)P2 to generate PtdIns(3,4,5)P3 (PIP3) at the inner leaflet of the plasma membrane. PTEN (phosphatase and tensin homolog) opposes this reaction by converting PIP3 back to PIP2, making PTEN a critical negative regulator of PI3K/AKT signaling in endothelial cells.

AKT Activation and Downstream Effectors

PIP3 recruits AKT (PKB) and its activating kinase PDK1 to the membrane through their pleckstrin homology (PH) domains. PDK1 phosphorylates AKT T308, while mTORC2 phosphorylates AKT S473 — both phosphorylations are required for full AKT activation. Activated AKT phosphorylates numerous substrates relevant to endothelial biology:

• •eNOS (S1177): Increases eNOS catalytic activity, NO production → vasodilation and vascular permeability
• •BAD (S136): Anti-apoptotic; prevents BAD-BCL-XL complex disruption → endothelial survival
• •GSK3β (S9): Inhibits GSK3β → prevents β-catenin phosphorylation and degradation → promotes junction stability
• •FOXO1/3 (T24/S256): Nuclear exclusion → represses pro-apoptotic gene expression
• •mTORC1 (via TSC1/2 inhibition): Promotes cap-dependent translation → protein synthesis for cell growth

eNOS and Nitric Oxide

Endothelial nitric oxide synthase (eNOS/NOS3) is the central mediator of VEGF-induced vascular permeability and vasodilation. In unstimulated endothelial cells, eNOS is palmitoylated and myristoylated, targeting it to caveolae where it associates with caveolin-1 in an inhibited state. VEGF-induced AKT S1177 phosphorylation disrupts caveolin-1 binding, activates eNOS, and stimulates calmodulin binding — together driving NO synthesis from L-arginine.

NO signals primarily through soluble guanylate cyclase (sGC) activation → cGMP → PKG, which phosphorylates myosin light chain phosphatase (MLCP) → reduced myosin light chain phosphorylation → actomyosin relaxation → increased endothelial permeability. In angiogenesis, NO also promotes endothelial cell migration and proliferation through cGMP-dependent mechanisms.

---

MAPK/ERK Pathway: Endothelial Proliferation

ERK1/2 activation downstream of VEGFR2 drives endothelial cell proliferation and is essential for productive angiogenic responses. The pathway is initiated from pY1175 through PLCγ1:

VEGFR2 pY1175 → PLCγ1 → DAG → PKC → RAF → MEK → ERK1/2

PLCγ1 binds pY1175 through its SH2 domain and hydrolyzes PtdIns(4,5)P2 to diacylglycerol (DAG) and inositol trisphosphate (IP3). DAG activates protein kinase C (PKC), particularly PKCβ and PKCε in endothelial cells. PKC activates RAF (principally RAF1/CRAF in endothelial cells, distinct from the BRAF dependence in melanoma), which phosphorylates MEK1/2, which in turn dually phosphorylates ERK1/2 (T202/Y204 in ERK1; T185/Y187 in ERK2).

Active ERK1/2 translocates to the nucleus and phosphorylates transcription factors driving the angiogenic transcriptome: ELK1, CREB, c-FOS, ETS factors (ETS1, ETV2/ER71). ERK-dependent proliferation is complemented by a separate SHB adaptor → FAK → paxillin pathway from pY1175 that promotes focal adhesion turnover and endothelial cell migration.

An alternative VEGFR2 → GRB2-SOS-RAS-RAF-MEK-ERK pathway operates in parallel through pY1175/SHB and pY951/VRAP-SRC axis, converging at RAF activation. The relative contributions of PLCγ vs. SOS-mediated RAS activation to ERK signaling remain context-dependent.

---

DLL4-Notch Signaling: Tip and Stalk Cell Specification

Productive angiogenesis requires not simply endothelial proliferation and migration, but the coordinated organization of sprouting endothelial cells into tip cells (which lead sprouts and sense gradients) and stalk cells (which proliferate and form the vessel lumen). This specification is governed by a lateral inhibition mechanism involving VEGF-A and the DLL4 (Delta-like ligand 4)/Notch pathway.

The Tip/Stalk Decision

VEGF-A gradients in hypoxic tissue preferentially activate endothelial cells closest to the source. High VEGFR2 signaling in these cells induces expression of DLL4 — a Notch ligand. DLL4 on the prospective tip cell activates Notch1 on neighboring cells (prospective stalk cells) through juxtacrine signaling. Notch1 activation in stalk cells suppresses VEGFR2 expression (through HES/HEY transcriptional repressors) and upregulates VEGFR1 (the decoy receptor), making stalk cells less responsive to VEGF-A and stabilizing them in a proliferative but non-migratory phenotype.

The tip cell, with low Notch activity and high VEGFR2 and VEGFR3 expression, extends filopodia toward the VEGF-A gradient, guided by a VEGFR3-dependent pathway (VEGF-C/D from stalk cells and the microenvironment signal through VEGFR3 on tip cells to promote filopodial extension).

Notch Processing and Signaling

DLL4 engagement induces sequential proteolytic cleavage of Notch1: ADAM10/ADAM17 ectodomain shedding (S2 cleavage) followed by γ-secretase intramembrane cleavage (S3) releases the Notch intracellular domain (NICD). NICD translocates to the nucleus, where it displaces co-repressors from the transcription factor CSL (RBPJ) and recruits co-activators MAML1/2/3 → transcription of HES1, HEY1, HEY2, HEYL → repression of VEGFR2, DLL4, and NRP1 → stalk cell phenotype.

The DLL4/Notch pathway thus creates a self-organizing lateral inhibition pattern: the first cell to receive a VEGF-A signal becomes the tip cell and inhibits its neighbors from also becoming tip cells. This ensures only one leading cell per sprout, preventing chaotic multi-tip sprouting.

Pharmacological relevance: DLL4-blocking antibodies (e.g., REGN421/enoticumab, OMP-21M18/demcizumab) paradoxically increase vessel density but decrease vessel perfusion and tumor growth in preclinical models, by preventing appropriate tip/stalk specification and generating non-functional, hyperbranched vasculature.

---

HIF-1α: Hypoxic Transcriptional Control of VEGF Expression

VEGF-A transcription is dominantly regulated by the hypoxia-inducible factor (HIF) family, providing the link between oxygen sensing and angiogenic output.

HIF-1α Structure and Oxygen-Dependent Degradation

HIF-1α (120 kDa) contains an N-terminal basic helix-loop-helix (bHLH) domain for DNA binding, PAS (PER/ARNT/SIM) domains A and B for dimerization with HIF-1β/ARNT, an oxygen-dependent degradation domain (ODD), and C-terminal transactivation domains (N-TAD and C-TAD).

Under normoxic conditions (>8% O2), prolyl hydroxylase domain enzymes (PHD1/2/3, also called EGLN2/1/3) hydroxylate two proline residues in the ODD (P402 and P564 in human HIF-1α) using O2 and 2-oxoglutarate as co-substrates. Hydroxylated HIF-1α is recognized by the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex (VHL-Elongin B/C-Cullin 2-RBX1), which polyubiquitinates HIF-1α and targets it for proteasomal degradation (t½ < 5 min in normoxia).

Factor inhibiting HIF (FIH/HIFAN) provides a second layer of oxygen-dependent repression by hydroxylating N803 in the C-TAD, preventing co-activator p300/CBP recruitment and blocking transactivation — even when HIF-1α escapes proteasomal degradation.

Hypoxic HIF-1α Stabilization

Below ~3% O2, PHD activity falls (O2 is limiting for the hydroxylase reaction) → HIF-1α accumulates → dimerizes with constitutively expressed HIF-1β → recruits p300/CBP co-activators → binds hypoxia response elements (HREs; core sequence 5'-RCGTG-3') in target gene promoters/enhancers.

The VEGF-A gene contains a functional HRE in its 3' untranslated region (3'UTR) and multiple HREs in the promoter. HIF-1α binding drives strong VEGF-A transcriptional induction (commonly 5–30-fold in hypoxic tumors). HIF-2α (encoded by EPAS1), which shares the HRE binding consensus, shows selective expression in endothelial cells and certain tumor histotypes (clear cell renal cell carcinoma, hemangioblastoma) and drives VEGF-A and EPO expression preferentially over HIF-1α target genes like BNIP3 and LDHA.

Oncogenic Activation of HIF-1α

In tumors, HIF-1α can be activated independent of hypoxia through:

• •VHL loss-of-function (mutations in ~85% of clear cell RCC): prevents VHL recognition of OH-Pro-HIF-1α → constitutive HIF-1α accumulation and VEGF expression even at ambient O2
• •RAS/MAPK activation: ERK phosphorylates p300/CBP, promoting HIF-1α transactivation complex assembly
• •PI3K/AKT/mTOR activation: mTORC1 promotes HIF-1α cap-dependent translation through 4E-BP1 and S6K phosphorylation
• •Succinate/fumarate accumulation (SDH, FH mutations): competitively inhibit PHD2 (2-oxoglutarate-dependent) → PHD2 inactivation → HIF-1α stabilization in normoxia

---

Downstream Effectors: Vascular Permeability, Migration, and Tube Formation

Vascular Permeability: VE-Cadherin Regulation

VEGF-A induces rapid (minutes) vascular permeability through phosphorylation and internalization of VE-cadherin (CDH5), the major component of endothelial adherens junctions. Activated SRC phosphorylates VE-cadherin Y658 and Y685, disrupting its interaction with β-catenin/plakoglobin and triggering clathrin-mediated endocytosis. Simultaneously, PAK (p21-activated kinase), activated through VEGFR2 → RAC1 pathway, phosphorylates VE-cadherin-associated MLCK → myosin light chain phosphorylation → cytoskeletal contraction → junction opening.

Endothelial Cell Migration

VEGF-A-stimulated migration requires coordinated cytoskeletal reorganization mediated through:

• •VEGFR2 pY1214 → NCK → N-WASP → ARP2/3 complex → lamellipodia formation (Rac1-dependent)
• •VEGFR2 → RHOA/ROCK → MLC phosphorylation → stress fiber formation and rear retraction
• •FAK Y397 autophosphorylation (SRC-dependent, downstream of VEGFR2) → focal adhesion turnover → migration
• •SRC paxillin Y31/118 → scaffold for migration complex assembly

Tube Formation and Lumen Morphogenesis

Three-dimensional tube formation proceeds through a combination of: (1) cord formation (endothelial cell chain assembly), (2) intracellular vacuole formation and coalescence (in non-matrix conditions), and (3) cord hollowing or cell wrapping around an extracellular lumen. Signaling requirements include PI3K/AKT (survival), RHOA/CDC42 (polarity), VE-cadherin (junctional stability), and integrin α2β1/collagen IV interactions for basement membrane deposition.

---

Research Tools for VEGF/Angiogenesis Pathway Studies

---

Experimental Protocols for Angiogenesis Research

Protocol 1: VEGF-Stimulated VEGFR2 Phosphorylation (pY1175 Western Blot)

Objective: Detect VEGFR2 Y1175 autophosphorylation as a marker of receptor activation in response to VEGF-A165.

Cell preparation: Plate HUVECs (passage 3–6) at 2 × 10⁵/well in 6-well plates coated with 0.1% gelatin in EGM-2 complete medium. Allow 24 h for attachment and spreading.

Serum starvation: Aspirate EGM-2, wash once with PBS, replace with EBM-2 + 0.1% BSA (no growth factors). Incubate 4–6 h at 37°C to reduce baseline phosphorylation.

VEGF stimulation: Add recombinant VEGF-A165 at 50 ng/mL for the indicated times (0, 5, 15, 30, 60 min). For inhibitor experiments, pre-treat cells with kinase inhibitor (e.g., axitinib at 1 μM, DMH4 at 1 μM, or SU5416 at 10 μM) for 1 h before VEGF addition.

Lysis and immunoprecipitation: Aspirate medium, wash twice with ice-cold PBS. Lyse in NP-40 lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, PhosSTOP, cOmplete protease inhibitor). Transfer lysate to microtubes, rotate 30 min at 4°C, centrifuge 14,000 × g, 15 min. For VEGFR2 IP: incubate 500 μg lysate with 2 μg anti-VEGFR2 antibody (e.g., Cell Signaling #2479) + protein A/G beads overnight at 4°C. Wash 3× with lysis buffer.

Western blot: Elute with 2× Laemmli buffer, boil 5 min, load on 6% SDS-PAGE, transfer to PVDF. Block 1 h with 5% BSA/TBST. Primary: anti-pY1175 VEGFR2 (Cell Signaling #2478, 1:1000) overnight 4°C. Wash, HRP-secondary, ECL detection. Strip and re-probe with total VEGFR2 antibody. Expected: pY1175 band at ~240 kDa peaking at 5–15 min post-VEGF.

---

Protocol 2: HUVEC Tube Formation Assay (Matrigel Cord Formation)

Objective: Assess three-dimensional angiogenic sprouting capacity using reduced-growth-factor Matrigel.

Matrigel preparation: Thaw reduced-growth-factor Matrigel (Corning #356231) overnight at 4°C. Pre-cool pipette tips and plates. Working on ice, coat 96-well plates with 50 μL/well of Matrigel, avoiding bubbles. Polymerize 30 min at 37°C before cell addition.

Cell seeding: Trypsinize HUVECs, resuspend in EBM-2 + 2% FBS at 2 × 10⁴ cells/100 μL. Add test compounds (VEGF-A165, inhibitors, antibodies) to the cell suspension before seeding. Pipette 100 μL gently onto polymerized Matrigel. For VEGF-neutral baseline: include anti-VEGF antibody or use EBM-2 alone as negative control.

Imaging: Image at 4–8 h post-seeding using phase contrast microscopy (4× or 10× objective). Capture 2–3 fields per well. Quantify tube parameters using ImageJ with the Angiogenesis Analyzer plugin: total tube length (μm), number of nodes (branch points), number of meshes, and lacunarity index.

Controls: Positive control: 50 ng/mL VEGF-A165 + 5% FBS. Negative control: serum-free EBM-2 alone. Inhibitor control: 10 μM SU5416 in positive control conditions. Expected: positive control forms complete polygonal network with >50 branch points; negative control forms incomplete/collapsed cords; inhibitors reduce network complexity proportionally to potency.

---

Protocol 3: VEGF-A Hypoxia Induction and HIF-1α Stabilization

Objective: Demonstrate HIF-1α-dependent VEGF-A upregulation under hypoxic or chemical hypoxia mimetic conditions.

Hypoxia chamber: Place cells (any adherent cell line expressing VEGF-A) in a modular hypoxia chamber flushed with 1% O2/5% CO2/94% N2 for 4–24 h. Alternatively, use chemical PHD inhibitors: DMOG (1 mM, 8–16 h) or FG-4592 (100 μM, 4–8 h) under normoxia.

Nuclear fraction isolation for HIF-1α: After treatment, lyse cells in hypotonic buffer (10 mM Tris pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.5% NP-40), centrifuge 600 × g 5 min, wash nuclear pellet with isotonic buffer, extract nuclei in RIPA buffer. HIF-1α is detected in nuclear fraction (>90% under hypoxia) vs. cytoplasmic fraction (<10%). Under normoxia, HIF-1α is essentially undetectable due to rapid proteasomal degradation. Antibody: anti-HIF-1α (Abcam ab51608 or Cell Signaling #36169).

VEGF-A ELISA: Collect conditioned medium from treated cells (100–500 μL, 4–24 h collection). Centrifuge 300 × g to remove debris. Perform VEGF-A ELISA per manufacturer protocol (R&D Systems DVE00; detection range 31.2–2000 pg/mL). Expected: 5–30-fold VEGF-A induction in hypoxia vs. normoxia; similar induction with DMOG/FG-4592; abrogated by HIF-1α siRNA knockdown.

---

Protocol 4: Endothelial Cell Sprouting from Spheroids (3D Bead Assay)

Objective: Quantify three-dimensional angiogenic sprouting in a more physiologically relevant system than 2D Matrigel.

Bead coating: Incubate Cytodex 3 microcarrier beads (GE Healthcare) with HUVECs (400 cells/bead) in suspension culture for 4 h with intermittent agitation. Transfer bead-cell complexes to non-coated flasks overnight to prevent adherence. Wash spheroids in EBM-2.

Embedding in fibrin gel: Mix 2 mg/mL fibrinogen (from bovine plasma) in PBS with 0.15 units/mL aprotinin. Add 200 μL fibrinogen solution per well (24-well plate), then add VEGF-A165 (50 ng/mL) and bead spheroids (25/well). Polymerize by adding thrombin (0.625 units/mL). Allow gel to set at room temperature 15 min, then move to 37°C incubator.

Co-culture with fibroblasts (optional): Overlay polymerized gel with human dermal fibroblasts in EGM-2 (1 × 10⁴/mL, 500 μL/well). Fibroblasts provide soluble factors including VEGF-A, HGF, and FGF2 that amplify sprouting. Change medium every 2 days.

Quantification: Image at 24–120 h using phase contrast. Measure: cumulative sprout length (μm per bead), number of sprouts per bead, sprout branching (secondary sprout count), and maximum sprout length. VEGF-A inhibition (bevacizumab or axitinib) markedly reduces sprout number and length within 24 h.

---

Protocol 5: Flow Cytometry Assessment of VEGFR2 Surface Expression

Objective: Quantify VEGFR2 (and VEGFR1) surface density on endothelial cells or tumor cells using flow cytometry.

Cell preparation: Detach cells with Accutase (not trypsin, which may cleave extracellular domains). Wash in FACS buffer (PBS + 2% FBS + 0.1% sodium azide). Resuspend at 1 × 10⁶ cells/100 μL.

Staining: Incubate with Fc receptor block (10 min, 4°C). Add primary antibody: anti-VEGFR2 (e.g., BioLegend #359903, clone 7D4-6, PE-conjugated; or R&D Systems #FAB357P) at manufacturer-recommended concentration, 30 min, 4°C, protected from light. Wash 2× with FACS buffer. If unconjugated primary: add fluorochrome-conjugated secondary, 20 min, 4°C.

DLL4 treatment to assess Notch-mediated VEGFR2 downregulation: Pre-coat wells with recombinant DLL4 (5 μg/mL, 2 h at 37°C to cluster and activate Notch) before plating cells. After 24 h, assess VEGFR2 surface expression — Notch activation should reduce VEGFR2 by 30–60% (stalk cell phenotype induction).

Analysis: Run on flow cytometer, gate on live singlets (using viability dye). Report geometric mean fluorescence intensity (gMFI) and percent positive cells. Compare VEGFR2 gMFI across conditions. VEGF pre-treatment (10 min) causes receptor internalization; useful for validating ligand-dependent downregulation kinetics.

---

Angiogenesis in Disease Contexts: Tumor Vasculature and Therapeutic Resistance

Tumor Angiogenesis

Tumor-associated vasculature differs fundamentally from normal vasculature: it is tortuous, irregularly branched, poorly perfused, and functionally abnormal. The angiogenic switch in tumors results from the tipping of pro- vs. anti-angiogenic balance — driven by HIF-1α stabilization, increased VEGF-A secretion, loss of thrombospondin-1, and tumor microenvironment-derived pro-angiogenic signals (bFGF, angiopoietin-2, placental growth factor).

Tumor endothelial cells display distinct transcriptional signatures compared to normal endothelium: elevated DLL4, TEM (tumor endothelial markers; TEM1/8, TEM7), ROBO4, and altered integrin expression. These features may offer tumor-selective targeting opportunities.

Mechanisms of Anti-VEGF Resistance

Anti-VEGF therapy (bevacizumab, sunitinib) rarely produces durable responses in solid tumors. Resistance mechanisms include:

1. Upregulation of alternative angiogenic factors: bFGF, angiopoietin-1, ephrin-A1, and SDF-1α can drive VEGFR-independent angiogenesis via FGFR, TIE2, EphA, and CXCR4 respectively

2. Vessel co-option: Tumors grow along existing blood vessels without neo-angiogenesis, bypassing anti-VEGF therapy (common in brain metastases, hepatocellular carcinoma)

3. Pericyte-mediated stabilization: Increased PDGF-B signaling recruits pericytes that provide VEGF-A and stabilize vessels against VEGFR2 inhibition; PDGFR-β inhibition may restore sensitivity

4. Tumor microenvironment remodeling: Increased myeloid cell (TAM, MDSC) infiltration following anti-VEGF therapy restores pro-angiogenic signaling through Bv8/prokineticin, MMP9, and CXCL1/2

5. Tumor cell-intrinsic adaptations: VEGF-A-independent autocrine survival loops through AKT/mTOR, EGFR, or HER2 maintain tumor cell viability and promote vessel co-option

---

Key Experimental Considerations

VEGF-A isoform selection: For standard VEGFR2 signaling studies, VEGF-A165 is the appropriate ligand. For examining NRP1-independent VEGFR2 activation: use VEGF-A121. For matrix-binding and gradient studies: use VEGF-A189. Ensure recombinant VEGF-A is carrier-free (BSA-free preparations avoid confounding results in proliferation assays).

Endothelial cell passage considerations: HUVECs drift substantially between passages 3 and 8 — VEGFR2 expression decreases, proliferative response to VEGF diminishes, and tube formation capacity falls. Restrict experiments to passages 3–6 and document passage number in methods.

Oxygen measurement: When performing hypoxia experiments, validate chamber O2 levels with an O2 sensor rather than assuming instrument settings. HIF-1α stabilization can be used as a biological readout of hypoxia (nuclear HIF-1α detectable by immunofluorescence at O2 <3%).

Phosphorylation timing: VEGFR2 pY1175 peaks at 5–10 min post-VEGF-A165 stimulation in HUVECs and returns to baseline by 30–60 min due to receptor internalization and dephosphorylation by PTP1B/PTPRB. ERK activation shows similar kinetics. AKT phosphorylation persists somewhat longer (30–60 min). Design time course experiments accordingly.

---

Cited References

1. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161(2):851-858. PMID: 2735925

2. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006;312(5):549-560. PMID: 16336962

3. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem J. 2011;437(2):169-183. PMID: 21711246

4. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009;21(2):154-165. PMID: 19230644

5. Hellström M, Phng LK, Hofmann JJ, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007;445(7129):776-780. PMID: 17259973

6. Siekmann AF, Lawson ND. Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Nature. 2007;445(7129):781-784. PMID: 17259972

7. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399-408. PMID: 22304911

8. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464-468. PMID: 11292862

9. Bhatt DL, Bhatt DK. Bevacizumab: a monoclonal antibody against vascular endothelial growth factor. Semin Oncol. 2004;31(6 Suppl 16):1-14. PMID: 15717030

10. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006;8(11):1223-1234. PMID: 17060908

11. Phng LK, Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell. 2009;16(2):196-208. PMID: 19217423

12. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417-427. PMID: 21629292

13. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592-603. PMID: 18650835

---

All compounds and reagents described are for Research Use Only (RUO). Not intended for use in diagnostic procedures, therapeutic applications, or studies involving human subjects or animals. Researchers must comply with all applicable institutional and regulatory guidelines when handling biological materials and research reagents.